The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis
Open accessAbstract
BACKGROUND: A high circulating concentration of interleukin 6 is associated with increased risk of coronary heart disease. Blockade of the interleukin-6 receptor (IL6R) with a monoclonal antibody (tocilizumab) licensed for treatment of rheumatoid arthritis reduces systemic and articular inflammation. However, whether IL6R blockade also reduces risk of coronary heart disease is unknown. METHODS: Applying the mendelian randomisation principle, we used single nucleotide polymorphisms (SNPs) in the gene IL6R to evaluate the likely efficacy and safety of IL6R inhibition for primary prevention of coronary heart disease. We compared genetic findings with the effects of tocilizumab reported in randomised trials in patients with rheumatoid arthritis. FINDINGS: In 40 studies including up to 133,449 individuals, an IL6R SNP (rs7529229) marking a non-synonymous IL6R variant (rs8192284; p.Asp358Ala) was associated with increased circulating log interleukin-6 concentration (increase per allele 9·45%, 95% CI 8·34-10·57) as well as reduced C-reactive protein (decrease per allele 8·35%, 95% CI 7·31-9·38) and fibrinogen concentrations (decrease per allele 0·85%, 95% CI 0·60-1·10). This pattern of effects was consistent with IL6R blockade from infusions of tocilizumab (4-8 mg/kg every 4 weeks) in patients with rheumatoid arthritis studied in randomised trials. In 25,458 coronary heart disease cases and 100,740 controls, the IL6R rs7529229 SNP was associated with a decreased odds of coronary heart disease events (per allele odds ratio 0·95, 95% CI 0·93-0·97, p=1·53×10(-5)). INTERPRETATION: On the basis of genetic evidence in human beings, IL6R signalling seems to have a causal role in development of coronary heart disease. IL6R blockade could provide a novel therapeutic approach to prevention of coronary heart disease that warrants testing in suitably powered randomised trials. Genetic studies in populations could be used more widely to help to validate and prioritise novel drug targets or to repurpose existing agents and targets for new therapeutic uses. FUNDING: UK Medical Research Council; British Heart Foundation; Rosetrees Trust; US National Heart, Lung, and Blood Institute; Du Pont Pharma; Chest, Heart and Stroke Scotland; Wellcome Trust; Coronary Thrombosis Trust; Northwick Park Institute for Medical Research; UCLH/UCL Comprehensive Medical Research Centre; US National Institute on Aging; Academy of Finland; Netherlands Organisation for Health Research and Development; SANCO; Dutch Ministry of Public Health, Welfare and Sports; World Cancer Research Fund; Agentschap NL; European Commission; Swedish Heart-Lung Foundation; Swedish Research Council; Strategic Cardiovascular Programme of the Karolinska Institutet; Stockholm County Council; US National Institute of Neurological Disorders and Stroke; MedStar Health Research Institute; GlaxoSmithKline; Dutch Kidney Foundation; US National Institutes of Health; Netherlands Interuniversity Cardiology Institute of the Netherlands; Diabetes UK; European Union Seventh Framework Programme; National Institute for Healthy Ageing; Cancer Research UK; MacArthur Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“genetic evidence suggests that IL-6 may be causal for atherosclerotic cardiovascular disease, 24,25”
From Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide (2026) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genome-wide association studies (GWAS), meta-analysis, exome analysis and single nucleotide polymorphism (SNP) mapping have associated IL-6, IL-6R and gp130 with inflammatory diseases such as RA and coronary artery disease (263–269).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [265]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We also identified associations between IL6R pQTLs and CAD, rheumatoid arthritis and 7 other disease traits (Supplementary Table S12), thereby supporting the findings of the study69.”
From Genetic determinants of plasma protein levels in the Estonian population (2024) · cites this paper as [69]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“One large study reported a near significant effect ( P = 0.06) of a functional variant causing impaired signalling at the IL-6 receptor with reduced risk of developing diabetes mellitus 44.”
From Type 2 diabetes mellitus and psychological stress — a modifiable risk factor (2017) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“A previous study has shown a link between IL6R and CAD69.”
From Genetic determinants of plasma protein levels in the Estonian population (2024) · cites this paper as [69]
In the citing paper
“Confirming the role of IL-6 in health, in a large Mendelian randomization analysis, the IL6R SNP rs7529229, marking a non-synonymous IL6R variant (rs8192284; p.Asp358Ala), was associated with increased circulating IL-6 levels24.”
From Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty (2018) · cites this paper as [24]
In the citing paper
“Variants in the IL6R gene have been found to be associated with increased risk of coronary artery disease24, rheumatoid arthritis, atrial fibrillation, and abdominal aortic aneurysm, and with increased susceptibility to asthma, type 1 diabetes, and depression36,37.”
From Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty (2018) · cites this paper as [24]
In the citing paper
“CETP inhibitors exert their relatively modest cardioprotective effects on the basis that in addition to their HDL-C raising effects, more potent CETP inhibitors also lower apolipoprotein B 22,23,75 .”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [23]
In the citing paper
“The approach outlined here to obtaining a scaling estimate has generally held true for lipid-lowering therapies and risk of cardiovascular disease 22,23,40,92 but there are several potential reasons why the derivation of such a scaling for other therapeutic target-indication pairs may pose a challenge.”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [23]
In the citing paper
“However, using SNPs located in CETP associated with HDL-C at genome-wide significant levels in a drug-target MR suggests that modifying HDL-C via CETP, is likely to reduce risk of CHD 23,103 .”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [23]
In the citing paper
“CETP 23 variants associate with of CHD; APOA1 117 variants do not associate with risk of CHD”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [23]
In the citing paper
“Various statistical methods have been proposed to reduce weak instrument bias due to sample overlap and bias due to winner’s curse (see Section 3) 43– 45 .”
From Guidelines for performing Mendelian randomization investigations (2020) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,762
Haploview: analysis and visualization of LD and haplotype maps
Barrett, J. C., Fry, B., Maller, J., & Daly, M. J. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth457 · Cited by 14,563
The Human Genome Browser at UCSC
Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M., & Haussler, A. D. (2002) · Genome Research · doi:10.1101/gr.229102 · Cited by 10,400
Davey Smith, G., & Ebrahim, S. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg070 · Cited by 5,882
Cited by
Sorted by citations
Items 201–300 of 999
Biomarkers of Vascular Inflammation for Cardiovascular Risk Prognostication
Antonopoulos, A. S., Angelopoulos, A., Papanikolaou, P., Simantiris, S., Oikonomou, E. K., Vamvakaris, K., Koumpoura, A., Farmaki, M., Trivella, M., Vlachopoulos, C. V., et al. (2021) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2021.09.014 · Cited by 114
ADAM17 Activity and IL-6 Trans-Signaling in Inflammation and Cancer
Schumacher, N., & Rose‐John, S. (2019) · Cancers · doi:10.3390/cancers11111736 · Cited by 108
Strang, A. C., Bisoendial, R. J., Kootte, R. S., Schulte, D. M., Dallinga‐Thie, G. M., Levels, J. H. M., Kok, M. R., Vos, K., Tas, S. W., Tietge, U. J. F., et al. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.04.031 · Cited by 106
Su, D., Li, Z., Li, X., Chen, Y., Zhang, Y., Ding, D., Deng, X., Xia, M., Qiu, J., & Ling, W. (2013) · Mediators of Inflammation · doi:10.1155/2013/726178 · Cited by 103
Lessons learned from twins in autoimmune and chronic inflammatory diseases
Generali, E., Ceribelli, A., Stazi, M. A., & Selmi, C. F. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.04.005 · Cited by 108
Novel heart failure biomarkers: why do we fail to exploit their potential?
Piek, A., Du, W., de Boer, R. A., & Silljé, H. H. W. (2018) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2018.1460576 · Cited by 108
Guthrie, G. J. K., Roxburgh, C. S. D., Horgan, P. G., & McMillan, D. C. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.07.003 · Cited by 103
Genome-Wide Analysis of DNA Methylation and Acute Coronary Syndrome
Li, J., Zhu, X., Yu, K., Jiang, H., Zhang, Y., Deng, S., Cheng, L., Liu, X., Zhong, J., Zhang, X., et al. (2017) · Circulation Research · doi:10.1161/circresaha.116.310324 · Cited by 101
Emerging translational approaches to target STAT3 signalling and its impact on vascular disease
Dutzmann, J., Daniel, J., Bauersachs, J. K., Hilfiker‐Kleiner, D., & Sedding, D. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv103 · Cited by 104
Lacey, R. E., Kumari, M., & Bartley, M. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.08.007 · Cited by 99
Gelfand, J. M., Shin, D. B., Duffin, K. C., Armstrong, A. W., Blauvelt, A., Tyring, S. K., Menter, A., Gottlieb, S. L., Lockshin, B., Simpson, E. L., et al. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.01.025 · Cited by 99
Circulating Interleukin-6 Levels and Incident Ischemic Stroke
Παπαδόπουλος, Α., Palaiopanos, K., Björkbacka, H., Peters, A., de Lemos, J. A., Seshadri, S. S., Dichgans, M., & Georgakis, M. K. (2021) · Neurology · doi:10.1212/wnl.0000000000013274 · Cited by 104
Arends, C. M., Liman, T. G., Strzelecka, P. M., Kufner, A., Löwe, P., Huo, S., Stein, C. M., Piper, S. K., Tilgner, M., Sperber, P. S., et al. (2023) · Blood · doi:10.1182/blood.2022017661 · Cited by 99
Ye, Z., Kappelmann, N., Moser, S., Smith, G. D., Burgess, S., Jones, P. B., & Khandaker, G. M. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100992 · Cited by 105
Murray, E. C., Nosalski, R., MacRitchie, N. A., Tomaszewski, M., Maffia, P., Harrison, D. G., & Guzik, T. J. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab330 · Cited by 101
Autoimmunity and Inflammation Link to Cardiovascular Disease Risk in Rheumatoid Arthritis
DeMizio, D. J., & Geraldino-Pardilla, L. B. (2019) · Rheumatology and Therapy · doi:10.1007/s40744-019-00189-0 · Cited by 98
Georgakis, M. K., & Gill, D. (2021) · Stroke · doi:10.1161/strokeaha.120.032617 · Cited by 99
Chertow, G. M., Chang, A. M., Felker, G. M., Heise, M. A., Velkoska, E., Fellström, B., Charytan, D. M., Clementi, R. A., Gibson, C. M., Goodman, S. G., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03043-1 · Cited by 110
Wolf, J., Waetzig, G. H., Chalaris, A., Reinheimer, T. M., Wege, H., Rose‐John, S., & Garbers, C. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.718551 · Cited by 95
Neutrophil counts, neutrophil ratio, and new stroke in minor ischemic stroke or TIA
Zhu, B., Pan, Y., Jing, J., Meng, X., Zhao, X., Liu, L., Wang, D., Johnston, S. C., Li, H., Wang, Y., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005554 · Cited by 99
Verweij, N., Eppinga, R. N., Hagemeijer, Y. P., & van der Harst, P. (2017) · Scientific Reports · doi:10.1038/s41598-017-03062-8 · Cited by 91
Schunk, S. J., Kleber, M. E., März, W., Pang, S., Zewinger, S., Triem, S., Ege, P., Reichert, M., Krawczyk, M. J., Weber, S. N., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab107 · Cited by 100
Toshner, M. R., Church, C., Harbaum, L., Rhodes, C. J., Villar, S. S., Liley, J., Jones, R. J., Arora, A., Batai, K., Desai, A. A., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.02463-2020 · Cited by 97
The future of EPAC-targeted therapies: agonism versus antagonism
Parnell, E., Palmer, T. M., & Yarwood, S. J. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.02.003 · Cited by 92
Genetics of human longevity within an eco-evolutionary nature-nurture framework
Giuliani, C., Garagnani, P., & Franceschi, C. (2018) · Circulation Research · doi:10.1161/circresaha.118.312562 · Cited by 92
Beyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation
Reyes‐Soffer, G., & Westerterp, M. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105689 · Cited by 93
González-Jaramillo, N., Wilhelm, M., Arango-Rivas, A. M., González-Jaramillo, V., Mesa-Vieira, C., Minder, B., Franco, O. H., & Bano, A. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.02.036 · Cited by 92
Epigenetics and Immunometabolism in Diabetes and Aging
Guzik, T. J., & Cosentino, F. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7299 · Cited by 94
Lassale, C. M., Batty, G. D., Steptoe, A., Cadar, D., Akbaraly, T. N., Mika Kivimaki, B., & Zaninotto, P. (2018) · The Journals of Gerontology Series A · doi:10.1093/gerona/gly028 · Cited by 95
Beyond Mendelian randomization: how to interpret evidence of shared genetic predictors
Burgess, S., Butterworth, A. S., & Thompson, J. R. (2015) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2015.08.001 · Cited by 93
Thériault, S., Dina, C., Messika-Zeitoun, D., Le Scouarnec, S., Capoulade, R., Gaudreault, N., Rigade, S., Li, Z., Simonet, F., Lamontagne, M., et al. (2019) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.119.002617 · Cited by 90
Ross, S., D’Mello, M., Anand, S. S., Eikelboom, J., CARDIoGRAMplusC4D Consortium*, Stewart, A. F. R., Samani, N. J., Roberts, R., & Paré, G. (2015) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.114.000952 · Cited by 90
Interleukin-6 in atherosclerosis: atherogenic or atheroprotective?
Reiss, A. B., Siegart, N. M., & Leon, J. D. (2017) · Clinical Lipidology · doi:10.1080/17584299.2017.1319787 · Cited by 94
KONES, R. J. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s37119 · Cited by 91
Liu, J., Jing, L., & Tu, X. (2016) · BMC Cardiovascular Disorders · doi:10.1186/s12872-016-0217-3 · Cited by 90
Anti-inflammatory approaches to ischaemic stroke prevention
Kelly, P. J., Murphy, S., Coveney, S. A., Purroy, F. F., Lemmens, R., Tsivgoulis, G. K., & Price, C. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-314817 · Cited by 90
Using human genetics to improve safety assessment of therapeutics
Carss, K., Deaton, A. M., Río-Espínola, A. D., Diogo, D., Fielden, M. R., Kulkarni, D. A., Moggs, J. G., Newham, P., Nelson, M. R., Sistare, F. D., et al. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00561-w · Cited by 90
Singh‐Manoux, A., Shipley, M. J., Bell, J. A., Canonico, M., Elbaz, A., & Mika Kivimaki, B. (2016) · Canadian Medical Association Journal · doi:10.1503/cmaj.160313 · Cited by 93
Blockade of IL-6 signaling alleviates atherosclerosis in Tet2-deficient clonal hematopoiesis
Liu, W., Yalçınkaya, M., Fernández-Maestre, I., Olszewska, M., Ampomah, P. B., Heimlich, J. B., Wang, R., Vela, P. S., Xiao, T., Bick, A. G., et al. (2023) · Nature Cardiovascular Research · doi:10.1038/s44161-023-00281-3 · Cited by 91
Inflammatory Cytokines as Uremic Toxins: “Ni Son Todos Los Que Estan, Ni Estan Todos Los Que Son”
Castillo-Rodríguez, E., Pizarro-Sánchez, M. S., Sanz, A. B., Ramos, A. M., Sánchez-Niño, M. D., Martín-Cleary, C., Fernández‐Fernández, B., & Ortíz, A. (2017) · Toxins · doi:10.3390/toxins9040114 · Cited by 85
Xu, M., Qi, Q., Liang, J., Bray, G. A., Hu, F. B., Sacks, F. M., & Qi, L. (2013) · Circulation · doi:10.1161/circulationaha.112.000586 · Cited by 94
Groot, H. E., Ali, L. A., van der Horst, I. C. C., Schurer, R. A. J., van der Werf, H. W., Lipšic, E., van Veldhuisen, D. J., Karper, J. C., & van der Horst, I. C. C. (2018) · Clinical Research in Cardiology · doi:10.1007/s00392-018-1387-z · Cited by 88
Clinical approach to the inflammatory etiology of cardiovascular diseases
Ruscica, M., Corsini, A., Ferri, N., Banach, M., & Sirtori, C. R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104916 · Cited by 87
Genetics of Smoking and Risk of Atherosclerotic Cardiovascular Diseases
Levin, M. G., Klarin, D. M., Assimes, T. L., Freiberg, M. S., Ingelsson, E., Lynch, J. A., Natarajan, P., O’Donnell, C. J., Rader, D. J., Tsao, P. S., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.34461 · Cited by 85
Large uremic toxins: an unsolved problem in end-stage kidney disease
Wolley, M. J., & Hutchison, C. A. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy179 · Cited by 85
Systemic effects of IL-6 blockade in rheumatoid arthritis beyond the joints
Jarlborg, M., & Gabay, C. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155742 · Cited by 90
The Impact of Cytokines in Coronary Atherosclerotic Plaque: Current Therapeutic Approaches
Tsioufis, P., Theofilis, P., Tsioufis, K. P., & Tousoulis, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415937 · Cited by 93
Cupido, A. J., Asselbergs, F. W., Natarajan, P., CHARGE Inflammation Working Group, Ridker, P. M., Hovingh, G. K., & Schmidt, A. F. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15191 · Cited by 81
Romeo, S., Vidal‐Puig, A., Husain, M., Ahima, R. S., Arca, M., Bhatt, D. L., Diehl, A. M., Fontana, L., Foo, R., Frühbeck, G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf314 · Cited by 93
Kell, D. B., & Pretorius, E. (2014) · Integrative Biology · doi:10.1039/c4ib00173g · Cited by 81
Jukema, R., Ahmed, T. A.-H. N., & Tardif, J. (2019) · BMC Medicine · doi:10.1186/s12916-019-1433-3 · Cited by 82
Anticytokine Immune Therapy and Atherothrombotic Cardiovascular Risk
Ait‐Oufella, H., Libby, P., & Tedgui, A. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.311998 · Cited by 84
Fu, J., Baines, K. J., Wood, L. G., & Gibson, P. G. (2013) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2012.0104 · Cited by 83
Simon, T. G., Trejo, M. E. P., McClelland, R. L., Bradley, R. D., Blaha, M. J., Zeb, I., Corey, K. E., Budoff, M. J., & Chung, R. T. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.01.046 · Cited by 82
Karpouzas, G. A., Ormseth, S. R., Hernández, E., & Budoff, M. J. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41293 · Cited by 79
Sun, Y., Liu, Y., Dian, Y., Zeng, F., Deng, G., & Lei, S. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001514 · Cited by 79
Chronic inflammation as a determinant of future aging phenotypes
Akbaraly, T. N., Hamer, M., Ferrie, J. E., Lowe, G. D. O., Batty, G. D., Hagger‐Johnson, G., Singh‐Manoux, A., Shipley, M. J., & Mika Kivimaki, B. (2013) · Canadian Medical Association Journal · doi:10.1503/cmaj.122072 · Cited by 79
Epidemiology, Traditional and Novel Risk Factors in Coronary Artery Disease
Mack, M. C., & Gopal, A. (2015) · Heart Failure Clinics · doi:10.1016/j.hfc.2015.08.002 · Cited by 78
Targeting inflammatory pathways for the treatment of cardiovascular disease
Ridker, P. M. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht398 · Cited by 78
Associations of Adiposity, Circulating Protein Biomarkers, and Risk of Major Vascular Diseases
Pang, Y., Kartsonaki, C., Lv, J., Fairhurst-Hunter, Z., Millwood, I. Y., Yu, C., Guo, Y., Chen, Y., Bian, Z., Yang, L., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.6041 · Cited by 75
Inflammation-Accelerated Senescence and the Cardiovascular System: Mechanisms and Perspectives
Pinto, R. D., & Ferri, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123701 · Cited by 77
Genetic variants mimicking therapeutic inhibition of IL-6 receptor signaling and risk of COVID-19
Bovijn, J., Lindgren, C. M., & Holmes, M. V. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30345-3 · Cited by 75
Jia, X., Buckley, L. F., Sun, C., Rifai, M. A., Yu, B., Nambi, V., Virani, S. S., Selvin, E., Matsushita, K., Hoogeveen, R. C., et al. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad197 · Cited by 75
Pluijmert, N. J., Atsma, D. E., & Quax, P. H. A. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.647785 · Cited by 75
Kerola, A. M., Rollefstad, S., & Semb, A. G. (2021) · European Cardiology Review · doi:10.15420/ecr.2020.44 · Cited by 75
Doi, T., Langsted, A., & Nordestgaard, B. G. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.05.010 · Cited by 76
Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases
Ji, E., & Lee, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115770 · Cited by 77
Spoto, B., Mattace-Raso, F. U. S., Sijbrands, E. J. G., Leonardis, D., Testa, A., Pisano, A., Pizzini, P., Cutrupi, S., Parlongo, R. M., D’Arrigo, G., et al. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07000714 · Cited by 74
Anti-cytokine therapies in T1D: Concepts and strategies
Nepom, G. T., Ehlers, M. R., & Mandrup-Poulsen, T. R. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.02.003 · Cited by 72
Gager, G. M., Biesinger, B., Hofer, F., Winter, M., Hengstenberg, C., Jilma, B., Eyileten, C., Postula, M. A., Lang, I. M., & Siller-Matula, J. M. (2020) · Vascular Pharmacology · doi:10.1016/j.vph.2020.106806 · Cited by 76
Akbaraly, T. N., Shipley, M. J., Ferrie, J. E., Virtanen, M., Lowe, G. D. O., Hamer, M., & Mika Kivimaki, B. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.10.002 · Cited by 77
Antibodies to citrullinated peptides and risk of coronary heart disease
Cambridge, G., Acharya, J., Cooper, J. A., Edwards, J., & Humphries, S. E. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.02.009 · Cited by 70
Interleukin-6 and Cardiovascular Events in Healthy Adults
Khan, M. S., Talha, K. M., Maqsood, M. H., Rymer, J. A., Borlaug, B. A., Docherty, K. F., Pandey, A., Kahles, F., Čikeš, M., Lam, C. S. P., et al. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101063 · Cited by 69
C-Reactive Protein and Coronary Heart Disease: All Said—Is Not It?
Strang, F., & Schunkert, H. (2014) · Mediators of Inflammation · doi:10.1155/2014/757123 · Cited by 72
Schooling, C. M., Luo, S., Yeung, S. L. A., Thompson, D. J., Karthikeyan, S., Bolton, T. R., Mason, A. M., Ingelsson, E., & Burgess, S. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.05.051 · Cited by 66
Georgakis, M. K., Malik, R., Li, X., Gill, D., Levin, M. G., Vy, H. M. T., Judy, R., Ritchie, M. D., Verma, S. S., Nadkarni, G. N., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.052604 · Cited by 68
Silvis, M. J. M., Fiolet, A. T. L., Opstal, T. S. J., Dekker, M., Suquilanda, D., Živkovic, M., Duyvendak, M., The, S. H. K., Timmers, L., Bax, W. A., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.08.005 · Cited by 71
Mitsis, A., Kadoglou, N. P. E., Lambadiari, V., Alexiou, S., Theodoropoulos, K. C., Avraamides, P., & Kassimis, G. (2022) · Cytokine · doi:10.1016/j.cyto.2022.155848 · Cited by 73
Cupido, A. J., Reeskamp, L. F., Hingorani, A. D., Finan, C., Asselbergs, F. W., Hovingh, G. K., & Schmidt, A. F. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.2333 · Cited by 68
Ridker, P. M., Baeres, F. M. M., Hvelplund, A., Engelmann, M. D. M., Hovingh, G. K., Lincoff, A. M., Marx, N., Návar, A. M., Sattar, N. A., Tuttle, K. R., et al. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.4491 · Cited by 71
Marchiori, R. C., Pereira, L. A., Naujorks, A. A., Rovaris, D. L., Meinerz, D. F., Duarte, M. M. M. F., & da Rocha, J. B. T. (2015) · BMC Endocrine Disorders · doi:10.1186/s12902-015-0032-3 · Cited by 69
Mendelian randomisation applied to drug development in cardiovascular disease: a review
Mokry, L. E., Ahmad, O. S., Forgetta, V., Thanassoulis, G., & Richards, J. B. (2014) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102438 · Cited by 67
Hepcidin Deficiency Protects Against Atherosclerosis
Malhotra, R. K., Wunderer, F., Barnes, H. J., Bagchi, A., Buswell, M. D., O’Rourke, C., Slocum, C. L., Ledsky, C. D., Peneyra, K. M., Sigurslid, H. H., et al. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.312215 · Cited by 68
Interleukin-6: An Important Mediator of Allograft Injury
Jordan, S. C., Ammerman, N., Choi, J., Kumar, S., Huang, E., Toyoda, M., Kim, I. K., Wu, G. D., & Vo, A. A. (2020) · Transplantation · doi:10.1097/tp.0000000000003249 · Cited by 68
The interleukin 6 pathway and atherosclerosis
Scheller, J., & Rose‐John, S. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61246-x · Cited by 68
Interleukin 6 trans-signalling and risk of future cardiovascular events
Ziegler, L., Gajulapuri, A., Frumento, P., Bonomi, A., Wallén, H., Fairé, U. D., Rose‐John, S., & Gigante, B. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy191 · Cited by 67
Fiolet, A. T. L., Poorthuis, M. H. F., Opstal, T. S. J., Amarenco, P., Boczar, K. E., Buysschaert, I., Budgeon, C. A., Chan, N., Cornel, J. H., Jolly, S. S., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102835 · Cited by 68
Hashizume, M., Tan, S., Takano, J., Ohsawa, K., Hasada, I., Hanasaki, A., Ito, I., Mihara, M., & Nishida, K. (2014) · International Reviews of Immunology · doi:10.3109/08830185.2014.938325 · Cited by 68
Association of Interleukin-6 With the Progression of Carotid Atherosclerosis
Okazaki, S., Sakaguchi, M., Miwa, K., Furukado, S., Yamagami, H., Yagita, Y., Mochizuki, H., & Kitagawa, K. (2014) · Stroke · doi:10.1161/strokeaha.114.005991 · Cited by 73
Meißner, Y., Zink, A., Kekow, J., Rockwitz, K., Liebhaber, A., Zinke, S., Gerhold, K., Richter, A., Listing, J., & Strangfeld, A. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-1077-z · Cited by 67
Farahi, N., Paige, E., Balla, J., Prudence, E., Ferreira, R. C., Southwood, M. R., Appleby, S. L., Bakke, P. S., Gulsvik, A., Litonjua, A. A., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx053 · Cited by 67
Parisinos, C. A., Serghiou, S., Katsoulis, M., George, M. J., Patel, R. S., Hemingway, H., & Hingorani, A. D. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.05.022 · Cited by 67
Function and proteolytic generation of the soluble interleukin-6 receptor in health and disease
Schumertl, T., Lokau, J., Rose‐John, S., & Garbers, C. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2021.119143 · Cited by 68
CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer
Thompson, D. J., O’Mara, T. A., Glubb, D. M., Painter, J. N., Cheng, T. H. T., Folkerd, E. J., Doody, D., Dennis, J., Webb, P. M., _, _., et al. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0386 · Cited by 66
Ragino, Y. I., Stakhneva, E. M., Polonskaya, Y. V., & Kashtanova, E. V. (2020) · Biomolecules · doi:10.3390/biom10030374 · Cited by 70
Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?
Ridker, P. M. (2013) · Europe PMC (PubMed Central) · Cited by 67
Inflammation modulation and cardiovascular disease prevention
Awan, Z. A., & Genest, J. J. (2014) · European Journal of Preventive Cardiology · doi:10.1177/2047487314529350 · Cited by 65
Interleukin-6 Cytokine: A Multifunctional Glycoprotein for Cancer
Zarogoulidis, P. (2013) · Immunome Research · doi:10.4172/1745-7580.1000062 · Cited by 64
Antoun, H., Karouni, M., Abitbol, J., Zouiten, O., & Jemt, T. (2017) · Clinical Implant Dentistry and Related Research · doi:10.1111/cid.12477 · Cited by 65
The Role of Emerging Risk Factors in Cardiovascular Outcomes
Lacey, B., Herrington, W. G., Preiss, D., Lewington, S., & Armitage, J. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0661-2 · Cited by 69
Metadata
- Authors
- Swerdlow, D. I.
- Affiliations
- University College London (GB)
- Corresponding author
- Daniel I. Swerdlow
- ORCID
- Daniel I. Swerdlow
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 379
- Issue
- 9822
- Pages
- 1214-1224
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC3316968
- OpenAlex
- W2143727405
- Cited by
- 1,146
- References
- 100
- Citations by year
- 2026: 78 · 2025: 86 · 2024: 94 · 2023: 89 · 2022: 84 · 2021: 110 · 2020: 89 · 2019: 80 · 2018: 74 · 2017: 77 · 2016: 67 · 2015: 56 · 2014: 63 · 2013: 65 · 2012: 32
- FWCI
- 8.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Bristol Research (University of Bristol) (publishedVersion, cc-by)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Lithuanian University of Health Sciences (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- MRC population health scientist fellowship (G0802432)
- National Institutes of Health (NIH), the MRC, and the British Heart Foundation (BHF (RG/10/12/28456)
- BHF (Schillingford) clinical training fellowship (FS/07/011)
- US National Heart, Lung, and Blood Institute (HHSN268200900009C)
- National Human Genome Research Institute (U01HG005152)
- Cancer Research UK (C1298/A8362, C150/A5660)
- IKEM (Czech Republic) (00023001)
- National Institute for Healthy Ageing (05060810)
- NIH/NHLBI (5215810-55000000041)
- BHF (RG 08/008 and PG/07/133/24260, RG/04/003)
- Netherlands Organisation for Health Research and Development (90700342)
- BHF senior fellowship (FS 05/125)
- British Heart Foundation (RG/10/12/28456)
- contract no. (HHSN268200625226C)
- NHLBI in collaboration with MESA investigators (N01 HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, and RR-024156)
- Wellcome Trust (064947/Z/01/Z and 081081/Z/06/Z)
- National Institute on Aging (1R01 AG23522-01)
- Intramural Research Program of the National Institute on Aging, NIH, Department of Health and Human Services (Z01 AG000954-06, ISGS (R01 NS42733), (R01 NS39987), Z01 AG000015-50)
- European Commission (QLG1-CT-2002-00896)
- Dutch Kidney Foundation (Grant E033)
- GENECURE (FP-6 LSHM CT 2006 037697)
- NIH (grant LM010098)
- The Netherlands Organisation for Health Research and Development (grant 916.761.70)
- European Union's Seventh Framework Programme (FP7/2007-2013)
- NHLBI (RFP-NHLBI-WH-11-10, HL36310)
- Veni grant Organization for Scientific Research (NWO) (2001.064)
- NIH; National Institute on Aging (AG13196)
- MRC (grant NHLBI 33014)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- IL-6 receptor, tocilizumab, coronary artery disease, primary prevention, C-reactive protein, fibrinogen, rheumatoid arthritis, genetic variants, monoclonal antibodies
- MeSH terms
- Coronary Disease, Gene Frequency, Genotype, Humans, Phenotype, Genetic Variation, Signal Transduction, Randomized Controlled Trials as Topic, Treatment Outcome, Inflammation Mediators, Receptors, Interleukin-6, Polymorphism, Single Nucleotide, Genetic Association Studies, Mendelian Randomization Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
